Health In Tech, Inc. SEC Filings

Health In Tech insider Jonathan Del Lockett reported a grant of 7,000 restricted shares of Class A common stock on 08/15/2025. The restricted shares were granted under the Health in Tech Equity Incentive Plan and carry vesting conditions tied to the successful launch and full operation of two specified company programs: 50% of the restricted shares vest monthly over 12 months after the first program is launched, and the remaining 50% vest monthly over 12 months after the second program is launched. Following the reported transaction, Mr. Lockett beneficially owns 93,539 shares (including 22,105 restricted shares and 71,434 unrestricted Class A shares); the filing notes he also holds 165,085 options to purchase Class A common stock that are excluded from the ownership total.

Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for three senior executives tied to the development of two new programs, referred to as Program 1 and Program 2. Chief Executive Officer Tim Johnson was granted 17,000 shares for each program, Chief Financial Officer Linlin (Julia) Qian was granted 10,000 shares for Program 1 and 17,000 shares for Program 2, and Chief Technology Officer (Mo) Imran Yousuf was granted 3,500 shares for each program.

Half of each executive’s grant will vest in equal monthly installments over twelve months starting when the first of the two programs is successfully launched and fully operational in the marketplace. The remaining half will vest in equal monthly installments over twelve months starting when the other program is successfully launched and fully operational. These awards were made under the company’s Equity Incentive Plan and follow previously approved restricted stock award agreements.

Health In Tech, Inc. reported accelerating revenue and margin expansion for the six months ended June 30, 2025. Total revenues rose to $17.33 million from $10.13 million a year earlier, driven by higher fees and underwriting modeling services, producing gross profit of $11.67 million and net income of $1.13 million, up from $438,543. Cash and cash equivalents increased modestly to $8.14 million, supported in part by net IPO proceeds of $8.21 million received previously.

The balance sheet shows growth in non-current and other receivables to $3.85 million, reflecting purchases of deferred administrative surplus; accounts payable rose to $4.33 million. The company recognized a refund liability of $955,743 tied to a variable reconciliation clause with a carrier and recorded stock-based compensation expense of $1.20 million during the period. Significant customer and vendor concentrations and collection uncertainty on purchased receivables are material risks disclosed in the filing.

Health In Tech director William D. Howard acquired 128,474 shares of Class A Common Stock on June 23, 2025 at $0.62 per share through a restricted stock grant under the company's Equity Incentive Plan.

Key details of the restricted stock grant:

• Vesting conditions: Full vesting after one year of service from December 23, 2024
• Alternative partial vesting: At first shareholders' meeting based on service period ratio
• Vesting requirement: Continuous service through vesting date
• Total value of grant: Approximately $79,654

This Form 4 filing was signed by Howard on June 25, 2025, meeting the SEC's two-day reporting requirement for insider transactions. The shares are held directly by the reporting person.

Timothy Hayes, Director of Health In Tech (HIT), acquired 128,474 shares of Class A Common Stock on June 23, 2025, at a price of $0.62 per share through a restricted stock grant under the company's Equity Incentive Plan.

Key vesting terms:

• Full vesting after one year of service from December 23, 2024
• Alternative partial vesting at first shareholders' meeting based on service time ratio
• Vesting conditional on continuous service through vesting date

The transaction was reported via Form 4 filing on June 25, 2025, within the required reporting window. This equity grant aligns the director's interests with shareholders and serves as part of the company's executive compensation strategy.

Director Sanjay Shrestha of Health In Tech received a grant of 128,474 restricted shares of Class A Common Stock at $0.62 per share on June 23, 2025, as reported in this Form 4 filing.

Key details of the stock grant:

• Shares were granted under the Health in Tech Equity Incentive Plan
• Vesting conditions include: - Full vesting after one year of service from April 8, 2025, or - Partial vesting at first shareholders' meeting based on service period ratio
• Direct ownership form of securities
• Vesting subject to continuous service requirement

This equity grant appears to be part of director compensation and aligns the director's interests with shareholders through a one-year vesting schedule.